1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

  • November 2015
  • 111 pages
  • ID: 3547091
  • Format: PDF
  • By Future Market Insight Global & Consulting Pvt Ltd

Summary

Table of Contents

Future Market Insights offers a 6-year forecast of the global peptide therapeutics market between 2015 and 2020. In terms of value, the market is expected to register a CAGR of 2.9% during the forecast period. This study demonstrates market dynamics and trends in all seven regions that influence the current environment and future status of the peptide therapeutics market over the forecast period.

Report Description

This Future Market Insights report examines the peptide therapeutics market for the period 2015–2025. The primary objective of the report is to offer insights into developments in the peptide therapeutics market that are significantly transforming global businesses and enterprises.

The global peptide therapeutics market report begins with defining ‘what are peptides’ and the various drug classes using peptides with regard to various ailments. It is followed by an overview of the global peptide therapeutics market. The overview section includes FMI analysis of key trends, drivers, restraints, trends and opportunities that are influencing growth of the peptide therapeutics market. It also includes an insight into upcoming drug pipeline of various drug makers using peptides and market shares of major players, apart from region-specific regulations. Impact analyses of key growth drivers and restraints based on a weighted average model have been included in the ‘global peptide therapeutics market report’ to better equip customers and readers with region specific trends and insights.

The primary driving factors for peptide therapeutics are significant increase in cases of metabolic disorders such as diabetes, obesity, and osteoporosis. Further, increase in cancer incidences have also triggered the growth of the peptide therapeutics market. Research indicates that brain disorders including developmental, psychiatric and neurodegenerative diseases represent a significant disease burden in terms of human suffering and economic cost across the globe. These pump demand for peptide-based drugs for major ailments. The primary factor hampering growth of the peptide market is rising product complexity and lack of skilled labour to manufacture these drugs.

The global peptide therapeutics market is segmented based on disease indications. These include cancer. Respitaory, CNS, cardio-vascular, metabolic disorders and others. A detailed analysis has been provided for all ten categories of diseases and sub-segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

The report has also been segmented based on various drug administration channels such oral and parenteral. A deep analyses along with market attractiveness for each of the categories have been provided in the report

The next section of the report highlights the peptide therapeutics market by region. It provides a market outlook for 2014–2020 and sets the forecast within the context of the peptide therapeutics market. The study discusses key regional trends contributing to growth of the peptide therapeutics market worldwide, as well as analyses the extent to which drivers are influencing this market in each region. Key regions assessed in this report include North America, Europe, Asia Pacific and Rest of the world.

The above sections – by disease indication, route of administration and region – evaluate the present scenario and growth prospects of the peptide therapeutics market for the period 2014 –2020. We have considered 2014 as the base year and provide data for the forecast period, i.e. 2014–2020.

To ascertain the market size of peptide therapeutics, we have also considered revenue generated by drug manufacturers. The forecast presented here assesses the total revenue by value across the peptide therapeutics market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the peptide therapeutics market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis, based on supply side, downstream industry demand and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market and to identify the right opportunities across the peptide therapeutics market.

The peptide therapeutics’ market segments in terms of disease indication, route of administration and region are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identification of various key trends in the peptide therapeutics market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the peptide therapeutics market.

To understand key growth segments in terms of growth and adoption for the ten disease indications across the globe in the near future, Future Market Insights developed the peptide therapeutics market ‘Attractiveness Index’. The resulting index should help providers identify real market opportunities.

In the final section of the report on peptide therapeutics, ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, based on categories of providers in the value chain of the peptide therapeutics product portfolio and key differentiators. Key categories of providers covered in the report are peptide therapeutics manufacturers. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the peptide therapeutics value chain and the potential players for the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in peptide therapeutics marketplace.

Detailed profiles of the drug makers are also included in the scope of the report to evaluate their long-term and short-term strategies, key offerings, SWOT analysis and recent developments. Key players include Amgen, Inc., AstraZeneca plc, Bachem Holding AG, Eli Lilly & Co., Ipsen, Lonza, Inc., Merck & Co., Novartis AG, Novo Nordisk A/S, Polypeptide Group, Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited and Teva Pharmaceuticals Limited.

Key Segments Covered

Disease Indication
Cancer
CNS indications
Cardiovascular Diseases
Metabolic Diseases
Infections
Haematological disorders
Gastrointestinal Disorders
Respiratory Disorders
Acromegaly
Others (includes pain therapeutics, osteoporosis, etc.)
By Route of Drug Administration
Oral
Parenteral

Key Regions Covered

North America
Europe
Asia Pacific
Rest of World

Key Companies

Amgen, Inc.,
AstraZeneca plc,
Bachem Holding AG, Eli Lilly & Co.,
Ipsen,
Lonza, Inc.,
Merck & Co.,
Novartis AG,
Novo Nordisk A/S,
Polypeptide Group,
Roche Holding AG,
Sanofi,
Takeda Pharmaceutical Company Limited and
Teva Pharmaceuticals Limited

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($5000)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2020

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2020, provides an ...

Chronic Urticaria Or Hives - Pipeline Review, H2 2019

Chronic Urticaria Or Hives - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Chronic Urticaria Or Hives - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2019, provides an overview of ...

Cryptosporidiosis - Pipeline Review, H2 2019

Cryptosporidiosis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Cryptosporidiosis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Pipeline Review, H2 2019, provides an overview of the Cryptosporidiosis ...


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on